Uses AI and synthetic biology to design novel antibody drug candidates for pharma partners and its own pipeline.
Uses AI and synthetic biology to design novel antibody drug candidates for pharma partners and its own pipeline.
Pharma partners pay research fees and milestone payments for antibodies the platform designs, with royalties only if those drugs are sold, so revenue is small and irregular. It pays for its own programmes by raising capital from investors.
Moat: narrow (data, IP / patents, process know-how). Combines generative AI with wet-lab synthetic biology to design antibodies faster than traditional discovery.
Headquarters: Vancouver, Washington, US · Founded: 2011 · Employees: 140
Size Absci (ABSI) is a United States Health Care company (Biotechnology) with a market value of $1.41B, the 2005th largest of 3,085 United States companies the cockpit tracks. Shares closed at $8.18 on 18 Nov 2026.
Performance Over six months the shares gained 65.2%, against -18.9% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue fell 47.2% over the last twelve months (peer median +28.0%); the operating margin is -9,155.4% (peer median -178.1%).
Valuation It trades at 835.7× enterprise value to sales against a peer median of 21.3× (2nd most expensive of 18).
Short interest Short interest is 20.9% of the free float (30 Oct 2026).
Next results Next results expected around 23 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $1.49M | $2.80M | $4.53M | $5.72M | $5.75M |
| Revenue growth | — | -38% | -21% | -1% | — |
| Gross profit | -$9.45M | -$8.94M | -$8.86M | -$8.28M | -$7.29M |
| EBITDA | -$125M | -$113M | -$95.5M | -$79.7M | -$93.7M |
| Net income | -$126M | -$115M | -$103M | -$111M | -$105M |
| Free cash flow | -$112M | -$94.0M | -$72.8M | -$65.5M | -$97.5M |
| Capital expenditure | -$63,000 | $1.11M | $404,000 | $860,000 | $16.2M |
| Total debt | $3.29M | $5.30M | $10.1M | $16.0M | $23.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Absci ABSI | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a |
| AbCellera Biologics ABCL | $3.60B | +141% | +92% | -298% | 43.4× | n/a |
| Recursion Pharmaceuticals RXRX | $1.76B | -5% | +56% | -725% | 18.8× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ABSI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.8% | -14.8% | 9th highest of 21 |
| 6-month return | +65.2% | -18.9% | 2nd highest of 19 |
| Distance from 52-week high | -34.8% | -47.0% | 4th highest of 21 |
| Revenue growth (TTM) | -47.2% | +28.0% | 2nd lowest of 18 |
| Operating margin | -9,155.4% | -178.1% | lowest of 19 |
| EV / Sales | 835.7× | 21.3× | 2nd most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.51B | -37% | +12% | 8% | 13.1× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| Korsana Biosciences KRSA | United States | $1.52B | +54% | -64% | -5,277% | 1,058.7× | n/a | n/a |